Discovery in mosquitoes could lead to new strategy against dengue fever and other mosquito-borne vectors
Researchers from the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health have made an important finding about Aedes aegypti mosquitoes — one that could one day lead to better methods for reducing the mosquito-to-human transmission of dengue, yellow fever, Zika, and other harmful and sometimes deadly viruses.
Ae. aegypti mosquitoes do not succumb to these viruses when infected and continue to move and feed normally. As such, the infected mosquitoes can pass their viral cargoes on to humans. The researchers discovered that an Ae. aegypti protein, Argonaute 2, has a key role — via several biological mechanisms — in keeping mosquitoes healthy and active despite these infections.
The discovery represents a significant advance in understanding mosquito biology. It also hints at a strategy that would aim to shut down Ae. aegypti mosquitoes’ defenses whenever they become infected by certain viruses — killing the mosquitoes and thereby reducing the transmission of those viruses by Ae. aegypti to humans. Instead of making mosquitoes more resistant to the viruses, the discovery opens a possible path for making mosquitoes more susceptible and less tolerant to virus infection, which would impair their ability to transmit disease.
The research was published online September 18 in Nature Communications.
“Researchers have long wondered why Ae. aegypti mosquitoes don’t get sick when they are infected by these viruses — our findings effectively solve this mystery and suggest a potential new mosquito-based disease control strategy that merits further study,” says study senior author George Dimopoulos, PhD, a professor in the Johns Hopkins Malaria Research Institute and in the Bloomberg School’s Department of Molecular Microbiology and Immunology.
The study’s lead author was Shengzhang Dong, PhD, a senior research associate in the Bloomberg School’s Department of Molecular Microbiology and Immunology.
Ae. aegypti mosquitoes transmit “arthropod-borne” or “arbo-” viruses including dengue virus, yellow fever virus, Zika virus, chikungunya virus, and Mayaro virus. Each year these pathogens sicken millions of people around the world each year, killing tens of thousands. There are no antiviral therapies for any of these viruses. Currently, a vaccine is available for yellow fever virus. One dengue vaccine is approved by the Food and Drug Administration for individuals between six and 16 who have had prior dengue infection. Disease control methods for Ae. aegyptiemphasize the use of insecticides, which have had limited success and have led to insecticide resistance.



